

Ari Gnanasakthy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2000908/publications.pdf>

Version: 2024-02-01

29
papers

1,035
citations

516561

16
h-index

477173

29
g-index

30
all docs

30
docs citations

30
times ranked

1404
citing authors

#	ARTICLE	IF	CITATIONS
1	A Review of Patient-Reported Outcome Labeling of FDA-Approved New Drugs (2016-2020): Counts, Categories, and Comprehensibility. <i>Value in Health</i> , 2022, 25, 647-655.	0.1	14
2	Use of Patient and Investigator Global Impression Scales: A Review of Food and Drug Administrationâ€™s Approved Labeling, 2009 to 2019. <i>Value in Health</i> , 2021, 24, 1016-1023.	0.1	7
3	FDA Guidance on Assessment of Patient-Reported Outcomes in Cancer Trials: A Breath of Fresh Air or a Storm in a Teacup?. <i>Patient</i> , 2021, 14, 695-697.	1.1	1
4	Quality of life is maintained with ixazomib maintenance in postâ€™ransplant newly diagnosed multiple myeloma: The TOURMALINEâ€™MM3 trial. <i>European Journal of Haematology</i> , 2020, 104, 443-458.	1.1	10
5	Patient-Reported Outcome Measures in Atopic Dermatitis and Chronic Hand Eczema in Adults. <i>Patient</i> , 2019, 12, 445-459.	1.1	52
6	A Review of Patient-Reported Outcomes Labeling for Oncology Drugs Approved by the FDA and the EMA (2012-2016). <i>Value in Health</i> , 2019, 22, 203-209.	0.1	73
7	Measurement Equivalence of Patient-Reported Outcome Measures Migrated to Electronic Formats: A Review of Evidence and Recommendations for Clinical Trials and Bring Your Own Device. <i>Therapeutic Innovation and Regulatory Science</i> , 2019, 53, 426-430.	0.8	22
8	A Review of Patient-Reported Outcome Labeling in the United States (2011â€™2015). <i>Value in Health</i> , 2017, 20, 420-429.	0.1	41
9	Secukinumab sustains early patient-reported outcome benefits through 1Â€™year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 655-661.	0.6	28
10	Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75â€™89 response: results from two phase 3 studies of secukinumab. <i>Journal of Dermatological Treatment</i> , 2017, 28, 492-499.	1.1	44
11	Impact of Measuring Patient-Reported Outcomes in Dermatology Drug Development. <i>Patient</i> , 2017, 10, 203-213.	1.1	17
12	Psychometric validation of the Psoriasis Symptom Diary using Phase III study data from patients with chronic plaque psoriasis. <i>International Journal of Dermatology</i> , 2016, 55, e147-55.	0.5	14
13	Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014). <i>Journal of Clinical Oncology</i> , 2016, 34, 1928-1934.	0.8	47
14	Development of the sporadic inclusion body myositis physical functioning assessment. <i>Muscle and Nerve</i> , 2016, 54, 653-657.	1.0	17
15	Assessing Changes in Chronic Spontaneous/Ideopathic Urticaria: Comparisons of Patient-Reported Outcomes Using Latent Growth Modeling. <i>Advances in Therapy</i> , 2016, 33, 214-224.	1.3	16
16	Patient-Reported Outcomes in Cancer Drug Development and US Regulatory Review. <i>JAMA Oncology</i> , 2015, 1, 375.	3.4	105
17	Overcoming Organizational Challenges of Integrating Patient-Reported Outcomes in Oncology Clinical Trials. <i>Therapeutic Innovation and Regulatory Science</i> , 2015, 49, 822-830.	0.8	4
18	Psychometric evaluation of the Sheehan Disability Scale in adult patients with attention-deficit/hyperactivity disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 887.	1.0	30

#	ARTICLE	IF	CITATIONS
19	Promotion of Patient-Reported Outcome Label Claims Based on Nonprimary Endpoints. Therapeutic Innovation and Regulatory Science, 2014, 48, 557-563.	0.8	0
20	Potential of patient-reported outcomes as nonprimary endpoints in clinical trials. Health and Quality of Life Outcomes, 2013, 11, 83.	1.0	29
21	Assessment of PRO Label Claims Granted by the FDA as Compared to the EMA (2006â€“2010). Value in Health, 2013, 16, 1150-1155.	0.1	70
22	Integration of patient-reported outcomes in multiregional confirmatory clinical trials. Contemporary Clinical Trials, 2013, 35, 62-69.	0.8	16
23	US FDA patient-reported outcome guidance: great expectations and unintended consequences. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 441-446.	0.7	40
24	Role of Patient-Reported Outcome Measures in the Assessment of Central Nervous System Agents. Therapeutic Innovation and Regulatory Science, 2013, 47, 613-618.	0.8	5
25	Capturing patients' perspectives of treatment in clinical trials/drug development. Contemporary Clinical Trials, 2012, 33, 23-28.	0.8	16
26	A Review of Patient-Reported Outcome Labels in the United States: 2006 to 2010. Value in Health, 2012, 15, 437-442.	0.1	106
27	Reasons for Rejection of Patient-Reported Outcome Label Claims: A Compilation Based on a Review of Patient-Reported Outcome Use among New Molecular Entities and Biologic License Applications, 2006â€“2010. Value in Health, 2012, 15, 443-448.	0.1	44
28	Patient-Reported Outcomes, Patient-Reported Information. Patient, 2011, 4, 11-17.	1.1	45
29	Patient reported outcomes: looking beyond the label claim. Health and Quality of Life Outcomes, 2010, 8, 89.	1.0	120